deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03175354

A Study in Subjects With Moderate Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Bilateral, Vehicle-Controlled Study of the Safety and Efficacy of ALX-101 Topical Gel Administered Twice Daily in Adult and Adolescent Subjects With Moderate Atopic Dermatitis

Sponsor: Ralexar Therapeutics, Inc.

Updated 7 times since 2017 Last updated: Oct 23, 2018 Started: Apr 26, 2017 Primary completion: Jun 29, 2018 Completion: Jun 29, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Atopic Dermatitis and Eczema, Atopic, this trial is completed. The trial is conducted by Ralexar Therapeutics, Inc. and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshotRecruiting~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotRecruiting~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshotRecruiting~Nov 2018 – ~Jan 2021 · 26 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Nov 2018 — Jan 2021 [monthly]

    Completed PHASE2

    Status: RecruitingCompleted

  5. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

Show 2 earlier versions
  1. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  2. Jul 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

    First recorded

Apr 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ralexar Therapeutics, Inc.
Data source: Ralexar Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .